The rationale provided by these data, and the importance of the timing of CTL administration following CT, together with possible associations with other biologicals, need to be verified in prospective studies which should include the administration of enriched CTLs specific for the subdominant antigen EBV-LMP2 and other antigens potentially present on tumor cells. The gene discussed is PSMB9; the disease is neoplasm.